title: Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrier.
abstract: To realize the potential of large molecular weight substances to treat neurological disorders, novel approaches are required to surmount the blood-brain barrier (BBB). We investigated whether fusion of a receptor-binding peptide from apolipoprotein E (apoE) with a potentially therapeutic protein can bind to LDL receptors on the BBB and be transcytosed into the CNS. A lysosomal enzyme, α-L-iduronidase (IDUA), was used for biological and therapeutic evaluation in a mouse model of mucopolysaccharidosis (MPS) type I, one of the most common lysosomal storage disorders with CNS deficits. We identified two fusion candidates, IDUAe1 and IDUAe2, by in vitro screening, that exhibited desirable receptor-mediated binding, endocytosis, and transendothelial transport as well as appropriate lysosomal enzyme trafficking and biological function. Robust peripheral IDUAe1 or IDUAe2 generated by transient hepatic expression led to elevated enzyme levels in capillary-depleted, enzyme-deficient brain tissues and protein delivery into nonendothelium perivascular cells, neurons, and astrocytes within 2 d of treatment. Moreover, 5 mo after long-term delivery of moderate levels of IDUAe1 derived from maturing red blood cells, 2% to 3% of normal brain IDUA activities were obtained in MPS I mice, and IDUAe1 protein was detected in neurons and astrocytes throughout the brain. The therapeutic potential was demonstrated by normalization of brain glycosaminoglycan and β-hexosaminidase in MPS I mice 5 mo after moderate yet sustained delivery of IDUAe1. These findings provide a noninvasive and BBB-targeted procedure for the delivery of large-molecule therapeutic agents to treat neurological lysosomal storage disorders and potentially other diseases that involve the brain.
authors: Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
authors: Daren
authors: D
authors: Wang
authors: Salim S
authors: SS
authors: El-Amouri
authors: Mei
authors: M
authors: Dai
authors: Chia-Yi
authors: CY
authors: Kuan
authors: David Y
authors: DY
authors: Hui
authors: Roscoe O
authors: RO
authors: Brady
authors: Dao
authors: D
authors: Pan
mesh_terms: D000818:Animals; D001057:Apolipoproteins E / Q000378:metabolism*; D001665:Binding Sites; D001812:Blood-Brain Barrier; D004195:Disease Models, Animal; D008247:Lysosomes / Q000201:enzymology*; D051379:Mice; D008059:Mucopolysaccharidosis I / Q000201:enzymology / Q000378:metabolism; D015202:Protein Engineering; D011973:Receptors, LDL / Q000378:metabolism*; D057900:Transcytosis
chemical_list: D001057:Apolipoproteins E; D011973:Receptors, LDL
references: Expert Opin Biol Ther. 2008 Jul;8(7):1003-9
references: 18549329
references: Drug Discov Today. 2007 Jan;12(1-2):54-61
references: 17198973
references: Gene Ther. 2007 Jan;14(2):99-107
references: 17167496
references: Mol Biotechnol. 2013 Jan;53(1):63-73
references: 22407720
references: Biotechnol Bioeng. 2008 Feb 1;99(2):475-84
references: 17680664
references: Biochemistry. 2005 Feb 15;44(6):2021-9
references: 15697227
references: Brain Res. 2008 Jan 10;1188:241-53
references: 18022143
references: AAPS J. 2008;10(1):166-77
references: 18446517
references: Drugs. 2002;62(5):733-42
references: 11929328
references: Nat Rev Neurosci. 2011 Nov 03;12(12):723-38
references: 22048062
references: Gene Ther. 2000 Nov;7(21):1875-83
references: 11110421
references: J Control Release. 2007 Mar 12;118(1):54-8
references: 17250920
references: Curr Med Chem. 2010;17(12):1125-38
references: 20175745
references: Hum Gene Ther. 2003 Sep 20;14(14):1297-305
references: 14503965
references: Mol Genet Metab. 2003 Aug;79(4):233-44
references: 12948739
references: Acta Paediatr Suppl. 2002;91(439):71-8
references: 12572847
references: Clin Pharmacokinet. 2007;46(7):553-76
references: 17596102
references: Curr Pharm Biotechnol. 2011 Jun;12(6):884-96
references: 21235445
references: Mol Ther. 2006 Oct;14(4):514-24
references: 16893684
references: Mol Pharm. 2011 Aug 1;8(4):1342-50
references: 21667973
references: Proc Natl Acad Sci U S A. 2007 May 1;104(18):7594-9
references: 17463083
references: Nat Rev Drug Discov. 2002 Feb;1(2):131-9
references: 12120094
references: N Engl J Med. 2004 May 6;350(19):1960-9
references: 15128896
references: Nat Rev Neurosci. 2009 May;10(5):333-44
references: 19339974
references: J Biol Chem. 1981 Jun 10;256(11):5646-55
references: 6263887
references: J Gene Med. 2008 Mar;10(3):249-59
references: 18076130
references: J Nanosci Nanotechnol. 2006 Sep-Oct;6(9-10):2712-35
references: 17048477
references: J Cell Sci. 2004 Oct 1;117(Pt 21):5071-8
references: 15383619
references: Nature. 1984 Feb 23-29;307(5953):742-5
references: 6321999
references: J Biol Chem. 2001 Jul 6;276(27):25043-8
references: 11350966
references: Blood. 1996 Jun 1;87(11):4894-902
references: 8639864
references: J Infect Dis. 2006 Feb 1;193(3):442-50
references: 16388493
references: Nat Rev Neurosci. 2010 Feb;11(2):87-99
references: 20087359
references: Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19958-63
references: 19903883
references: Biochemistry. 2004 Jun 15;43(23):7328-35
references: 15182176
references: Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12658-63
references: 15314220